Jared Gershowitz
Papers
3
Total Citations
174
H-Index
2
About
Jared Gershowitz is a leading clinical researcher in head and neck oncology, with a focused expertise in de-intensification strategies for human papillomavirus (HPV)-related oropharyngeal cancer. His work is centered on reducing treatment-related morbidity without compromising oncologic outcomes, particularly through innovative surgical and radiotherapeutic approaches. Gershowitz’s most impactful contribution is the landmark Phase 2 AVOID trial (2019, 167 citations), which demonstrated the safety of omitting the resected primary tumor bed from adjuvant radiotherapy after transoral robotic surgery for HPV-positive oropharyngeal squamous cell carcinoma. This study has significantly influenced clinical practice by enabling more targeted, less toxic treatment regimens. Additionally, his research on contralateral neck disease in tonsil cancer—including a 2019 study (5 citations) and a 2017 paper (2 citations)—has provided critical pathologic risk factors to guide patient selection for unilateral neck radiation therapy, further refining de-escalation protocols. Through these contributions, Gershowitz has advanced the paradigm of personalized, de-intensified care for HPV-associated head and neck cancers, directly improving quality of life for patients while maintaining excellent disease control. His work continues to shape evidence-based guidelines in radiation oncology and head and neck surgery.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3